Fidaxomicin: Additional Phase III data

Additional data from a double-blind, North American Phase III trial showed that fidaxomicin led to a non-significant faster time to resolution of diarrhea in patients whose diarrhea was not resolved in the first 24 hours of therapy compared with Vancocin vancomycin (79 vs. 105 hours, p=0.056). In a subgroup of patients receiving concomitant antibiotics, fidaxomicin significantly improved global cure rate compared with Vancocin (72% vs. 50%, p=0.022), but did not significantly lower CDI recurrence rate (40% vs. 23%, p=0.061) or lead to a significantly higher clinical cure rate compared with Vancocin (87% vs. 77%, p=0.171). ...